Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pheochromocytoma 3Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Endocrine System Diseases 1

Interventions

Everolimus 6Sunitinib 4Octreotide 4Leucovorin 4dabrafenib 3Fluorouracil 33-Iodobenzylguanidine 3trametinib 2selpercatinib 2lutetium Lu 177 dotatate 2avelumab 2alectinib 2PM 01183 2Oxaliplatin 2Irinotecan 2Fulvestrant 2Drug Therapy 2Doxorubicin 2Cisplatin 2trifluridine tipiracil drug combination 1tipifarnib 1telotristat ethyl 1surufatinib 1somapacitan 1ribociclib 1repotrectinib 1pralsetinib 1pentetreotide 1pegfilgrastim 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × 6-fluorodopamine × Endocrine × Clear all
NCT00028106 2017-07-02

131MIBG to Treat Malignant Pheochromocytoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
32 enrolled
Endocrine

Neoplasm Metastasis, Neoplasms, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡